K-Line Chart, actual market data is subject to the trading page.
Key Data
Prev. Open
$1.26
Prev. Close
$1.46
Prev. Day's Range
$1.22 - $1.46
52W Range
$0.44 - $3.04
Trading Volume
1.244M
MC
$231.776M
P/E Ratio
--
EPS
$-0.91
Company Overview
NASDAQ
Century Therapeutics Inc. (Ticker: IPSC) is an innovative biotechnology firm at the forefront of allogenic cell therapy, primarily focused on transforming cancer treatment regimens. Utilizing its advanced induced pluripotent stem cell (iPSC) technology, the company aims to develop groundbreaking off-the-shelf therapeutic solutions that enhance patient outcomes and broaden treatment accessibility. With a robust pipeline of clinical-stage assets and strategic partnerships that strengthen its competitive advantage, Century Therapeutics is well-prepared to make substantial contributions to the cell therapy market, offering attractive opportunities for investors seeking high-impact growth in the biotech sector.
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
Headquarters25 NORTH 38TH STREET, PHILADELPHIA, PA, UNITED STATES, 19104
IPSC focuses on developing genetically engineered cell therapies. The company operates in the biotechnology sector, targeting innovative treatments for various medical needs, including regenerative medicine and immune-related diseases.
IPSC operates within the biotechnology industry. It faces competition from companies that develop cell and gene therapies, such as CRISPR Therapeutics, Editas Medicine, and other firms engaged in regenerative medicine and immune-modulation technologies.
IPSC's revenue mainly comes from collaboration agreements, licensing partnerships, and advancements in its proprietary cell engineering platforms. The success of its therapies in clinical trials and regulatory approvals plays a vital role in driving revenue.
Risks include the inherent uncertainty of developing early-stage biotechnology products, lengthy regulatory approval processes, market competition, and challenges in scaling commercial operations. Biotech investments often carry high volatility based on trial results and market sentiment.
No, IPSC does not currently distribute dividends. As a biotechnology company primarily focused on research and development, it reinvests earnings into advancing its therapies and technologies instead of prioritizing dividend payments.
IPSC leverages its proprietary platform to engineer immune cells and regenerative cell products. Its novel approach to developing therapeutic solutions offers specialization that differentiates it from competitors in advanced regenerative medicine and immunotherapy.
IPSC has growth opportunities in expanding clinical trials, gaining regulatory approvals, and establishing partnerships with global pharmaceutical firms. Success in its therapies could lead to addressing unmet medical needs, opening up additional revenue streams.
Investors should consider IPSC’s pipeline progress, competitive position in the biotechnology market, and future potential for regulatory success. Due to its pre-commercial stage, valuation may fluctuate based on clinical updates, collaboration deals, and investor sentiment in the biotech space.
Risk Warning
1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
3.The information contained on this page is for reference only and does not constitute any investment advice.
